ArticleInternational journal of women's health2026
Short-Term Superiority of Transvaginal CO
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Approximately 20% of females experience stress urinary incontinence (SUI) during their lifetime. Emerging energy-based therapies, such as CO Objective: This study aims to compare the 6- and 12-month outcomes of transvaginal dot-matrix CO Methods: A retrospective analysis was conducted on 106 women (52 treated with laser therapy and 54 with RF therapy) who received standardized treatments. Primary outcomes included the reduction in the 1-hour urine pad test and changes in Questionnaire of International Consultation on Incontinence Questionnaire-Short Form (ICI-Q-SF) scores, while secondary outcomes comprised Patient Global Impression of Improvement (PGI-I) scores and complication rates. Results: After 6 months, the laser group exhibited a higher overall effective rate compared to the RF group (86.5% vs. 70.4%), with particularly superior outcomes in patients with mild SUI (pad test: 92.6% vs. 58.8%, p=0.017; ICI-Q-SF: 5.35 ± 3.11 vs. 6.98 ± 3.86, p<0.05). After 12 months, therapeutic equivalence was observed across all SUI severities, although RF demonstrated better sustained efficacy in moderate to severe cases (pad test: 70.27% vs. 40%, p=0.018; PGI-I: 2.87±0.89 vs. 3.37±1.01, p=0.009). Conclusion: CO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.